Cellectis S.A. (CLLS) stock
Close on Nov 12, 2026Market cap $133.45MP/E –Yield –
Cellectis S.A. grew revenue 75.8% to $72.95M over fiscal 2025. Free cash flow was -$41.76M, down 304.7% from a year earlier. At the latest close the market valued the company at $133.45M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $133.45M
- P/E ratio
- –
- Price to sales
- 1.83
- Price to book
- 3.25
- Dividend yield
- –
- Free cash flow yield
- -31.29%
Fundamentals
- Revenue
- $72.95M
- Net income
- -$67.59M
- EPS, diluted
- -$0.67
- Free cash flow
- -$41.76M
- Book value per share
- $0.41
- Diluted shares
- 101M
Trading
- Previous close
- $1.38
- Open
- $1.40
- Day's range
- $1.29 – $1.40
- Volume
- 42,647
- Average volume (20 days)
- 103,218
- Beta (5 years)
- 2.09
- 52-week range
- $0.88 – $5.45
- RSI (14 days)
- 54.3
- Volatility (1 year)
- 89.8%
- Relative volume
- 0.50×
- WACC
- 15.3%
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | CLLS | S&P 500 | Difference | CLLS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +12.7% | -2.7% | +15.4 pts | ||
| 3 months | -54.8% | -1.7% | −53.0 pts | ||
| Year to date | -72.5% | +11.9% | −84.4 pts | ||
| 1 year | -63.6% | +12.0% | −75.5 pts | ||
| 3 years | -47.0% | +78.2% | −125.2 pts | -19.1% | +21.2% |
| 5 years | -87.4% | +73.2% | −160.6 pts | -33.9% | +11.6% |
| 10 years | -93.0% | +309.6% | −402.7 pts | -23.4% | +15.1% |
Twelve years at a glance
Fiscal years 2014 to 2025, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cellectis filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Cellectis
Biological Products, (No Diagnostic Substances)
The provided text consists entirely of raw XBRL tags, taxonomy identifiers, financial line item members, and dates, with no narrative business disclosure. The metadata references entities such as Cellectis, Cellectis Biologics, and Calyxt, along with collaboration agreements involving AstraZeneca and Servier. However, the text does not contain any descriptive sentences outlining what the company does, its specific products, operating segments, or customer base.
Company profile, executives and historyCellectis stock: common questions
What is Cellectis's stock price?
CLLS closed at $1.33 on Nov 12, 2026, down 3.62% on the day. Over the past 52 weeks it traded between $0.88 and $5.45.
What is Cellectis's market cap?
Cellectis was worth $133.45M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is CLLS's P/E ratio?
Cellectis lost money over fiscal 2025 (diluted EPS -$0.67), so it has no meaningful P/E ratio.
How much revenue does Cellectis make?
Cellectis reported revenue of $72.95M for fiscal 2025, up 75.8% from a year earlier.
Does Cellectis pay a dividend?
No. Cellectis has not paid a cash dividend over the last twelve months.
How has CLLS stock performed over the past year?
Including dividends, CLLS returned -63.6% over the past year, against +12.0% for the S&P 500.
Who are Cellectis's competitors?
Companies most similar to Cellectis by business, industry and size include EDIT, IPSC, CGEN, GLUE, PLX.
See a number that looks wrong?